ART JOURNAL, published by Taylor & Francis Inc, is a distinguished journal in the field of Visual Arts and Performing Arts, boasting a commendable Q2 ranking in the latest 2023 category quartiles. With an ISSN of 0004-3249 and E-ISSN 2325-5307, this journal has been a vital platform for artistic discourse since its inception in 1960, detailing a rich lineage of research from 1960 to 1985 and from 1987 to the present. Acknowledged for its pedagogical value and scholarly contributions, the ART JOURNAL ranks #220 out of 667 in the Scopus database, placing it in the 67th percentile among its peers. Despite not currently providing open access options, the journal remains an invaluable resource for researchers, professionals, and students in the arts, fostering an environment for innovative thought and stimulating scholarly exchange.

LIFETIME DATA ANALYSIS, published by Springer, stands as a premier journal within the fields of Applied Mathematics and Medicine, with an impressive Q1 category ranking in both disciplines as of 2023. Established in 1995, this journal specializes in the analysis of time-to-event data and related methodologies, providing valuable insights applicable to clinical trials, epidemiology, and survival analysis. With its aim to foster innovative research that enhances statistical methods, LIFETIME DATA ANALYSIS supports the academic community by publishing high-quality articles that cover both theoretical advancements and practical applications. Although it does not offer open access, this journal reaches a wide audience globally, bridging the gap between mathematics and health sciences, and underlining its essential role in advancing interdisciplinary research.

PHARMACEUTICAL STATISTICS is a premier academic journal published by Wiley, focusing on the intersection of pharmacology and statistics. With the ISSN 1539-1604 and E-ISSN 1539-1612, this journal has established itself as a leading resource in the field since its inception in 2004, with a targeted convergence year extending to 2024. Notably, it ranks in the Q1 category for both pharmacology and statistics, reflecting its high impact and significance within these disciplines. The journal embraces a wide scope, encompassing statistical methodology and its application in pharmaceuticals, thus serving as an essential platform for researchers, professionals, and students committed to advancing their knowledge and practice. Its notable placement in Scopus rankings further reinforces its academic credibility, making it a valuable reference point for high-quality research. Although this journal does not currently offer open access options, it remains a vital source of insights and research advancements in the pharmaceutical sciences.

Therapeutic Innovation & Regulatory Science, published by Springer Heidelberg, is an esteemed journal that focuses on the intersection of therapeutic innovations and the regulatory frameworks that govern them. Established in 1970 and continuing its legacy of excellence through converged years, this journal plays a crucial role in supplying cutting-edge research, reviews, and discussions that advance understanding in the fields of pharmacology and healthcare regulation. With an impact factor reflective of its rigorous peer-review standards, this journal holds a prestigious Q1 ranking in Pharmacology, Toxicology, and Pharmaceutics (Miscellaneous) for 2023, reflecting its influence and the high quality of its published material. The journal's wide scope also embraces public health and environmental studies, making it an essential resource for researchers and professionals navigating these critical areas. Open access options enhance its visibility and accessibility, ensuring that the latest discoveries and regulatory insights are readily available to a global audience. For those at the forefront of medicinal science and regulatory affairs, Therapeutic Innovation & Regulatory Science is your avenue to understanding pivotal innovations that shape contemporary therapeutic practices.

Field Methods, an esteemed journal published by SAGE Publications Inc, specializes in the realm of Anthropology, presenting innovative research methodologies that shape contemporary anthropological inquiry. With an impressive impact factor reflected in its 2023 Scopus ranking as #81 out of 502 in the field of Social Sciences, this Q1 journal serves as a critical platform for academics, professionals, and students committed to advancing ethnographic research and methodological discourse. The journal, established in 1989, has embraced an interdisciplinary approach, encouraging submissions that explore both qualitative and quantitative methods across diverse contexts. While access options are not open access, subscribers benefit from comprehensive insights into the methodologies that underpin anthropological studies. As Field Methods approaches its converged years until 2024, it continues to play a pivotal role in informing and inspiring the next generation of scholars and practitioners aiming to enrich our understanding of cultures and communities worldwide.

The International Journal of Biostatistics, published by Walter de Gruyter GmbH, stands as a critical platform for advancements in the fields of biostatistics and applied statistics in medicine. With an ISSN of 2194-573X and an E-ISSN of 1557-4679, this journal has gained recognition for its rigorous peer-reviewed articles that bridge theoretical statistics and its practical applications in health sciences, maintaining a commendable Q2 quartile ranking in both Medicine and Statistics categories as of 2023. Hosted in Germany, the journal's pivotal role lies in disseminating innovative research findings that guide public health decisions and inform healthcare policy, thus appealing to a diverse readership including researchers, healthcare professionals, and students. Although the journal operates under a subscription model, it remains committed to providing valuable insights into the statistical methods that support evidence-based medicine and improve health outcomes globally. For those engaged in the evolving landscape of biostatistics, the International Journal of Biostatistics serves as an indispensable resource through its comprehensive coverage from 2005 to 2024.

Clinical Trials, published by SAGE Publications Ltd, is a prestigious journal that serves as a vital resource for researchers, professionals, and students in the fields of medicine and pharmacology. Operating since 2004 and converging through 2024, this journal boasts an impressive standing in the academic community, achieving a Q1 categorization in both Medicine (miscellaneous) and Pharmacology as of 2023. The journal's Scopus rankings reflect its influential contributions, with a rank of #128 out of 636 in General Medicine and a 79th percentile placement, alongside a rank of #172 out of 313 in Pharmacology, indicating its significant role in advancing clinical research. Based in the United Kingdom, Clinical Trials focuses on disseminating high-quality studies that enhance the understanding of clinical processes and therapeutic methodologies. Although it does not currently offer Open Access, the journal provides a platform for traditional publication, ensuring the dissemination of critical knowledge in the healthcare domain.

BIOSTATISTICS is a premier academic journal dedicated to the intersection of statistical methodologies and their applications in the field of biomedicine, published by Oxford University Press. With its ISSN 1465-4644 and E-ISSN 1468-4357, the journal has established itself as a crucial resource for researchers and professionals in the broad disciplines of statistics and probability, particularly within medical contexts. The journal proudly holds a Q1 ranking in multiple categories as of 2023, including Medicine (miscellaneous), Statistics and Probability, as well as Statistics, Probability, and Uncertainty, placing it at the forefront of statistical research. It has also achieved notable Scopus rankings, underscoring its influence and reach—ranking 27th in Mathematics (Statistics and Probability) and 94th in Medicine (General Medicine). Although it does not currently offer open access options, BIOSTATISTICS remains committed to advancing scholarly conversation and innovation in statistical science, making it an essential outlet for both established and emerging researchers. With contributions spanning from 2003 to 2024, this journal is actively seeking to foster an understanding of complex statistical approaches in biomedicine, enabling professionals in the field to apply robust statistical techniques to real-world problems.

Contemporary Clinical Trials Communications, published by ELSEVIER INC, serves as a pivotal resource in the evolving fields of medicine and pharmacology, especially with its commitment to open access since 2015. With the E-ISSN 2451-8654, this journal is dedicated to disseminating high-quality research that examines contemporary clinical trial methodologies and their applications in improving healthcare outcomes. Situated in the United States, its impressive ranking, with a Q2 status in both Medicine (miscellaneous) and Pharmacology for 2023, highlights its significance and impact within the scientific community. Ranking #199 out of 636 in General Medicine and #217 out of 313 in Pharmacology on the Scopus scale, the journal aims to foster innovative discussions and developments among researchers, professionals, and students, making it an essential tool for those seeking to stay at the forefront of clinical research and trials.

Clinical Pharmacology in Drug Development, published by WILEY, is a distinguished journal dedicated to advancing the field of pharmaceutical science and drug development. With a strong commitment to disseminating cutting-edge research, this journal serves as a crucial platform for professionals, researchers, and students aiming to enhance their understanding of pharmacological principles and innovations in medical therapeutics. Since its inception in 2012, the journal has consistently maintained a noteworthy presence in the academic community, currently achieving a Q2 ranking in both Pharmaceutical Science and Medical Pharmacology categories as of 2023. Although the journal operates under a subscription model, it is highly regarded for its rigorous peer-reviewed publications, offering insights into drug efficacy, safety, and regulatory challenges. Positioned at the intersection of clinical practices and pharmaceutical advancements, Clinical Pharmacology in Drug Development plays an essential role in bridging the gap between scientific research and real-world application, ensuring that the latest therapeutic strategies are optimized for patient care.